| Human immunodeficiency virus I infection

Apretude vs Odefsey

Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.

Deep comparison between: Apretude vs Odefsey with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsOdefsey has a higher rate of injection site reactions vs Apretude based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Odefsey but not Apretude, including UnitedHealthcare

Category

Apretude

Odefsey

At A Glance

RouteIM injection

FrequencyEvery 2 months

ClassHIV integrase strand transfer inhibitor

RouteOral

FrequencyOnce daily

ClassNRTI + NNRTI combination

Indications

Human immunodeficiency virus I infection

Human immunodeficiency virus I infection

Dosing

Human immunodeficiency virus I infection 600-mg (3-mL) gluteal IM initiation injections 1 month apart for 2 consecutive months, then 600-mg (3-mL) every 2 months; optional oral lead-in with cabotegravir 30 mg once daily for at least 28 days prior to first injection.

Human immunodeficiency virus I infection One tablet (emtricitabine 200 mg, rilpivirine 25 mg, tenofovir alafenamide 25 mg) orally once daily with a meal

Contraindications

Unknown or positive HIV-1 status
Previous hypersensitivity reaction to cabotegravir
Coadministration with anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin) due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations
Coadministration with antimycobacterials rifampin or rifapentine due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations

Coadministration with carbamazepine
Coadministration with oxcarbazepine
Coadministration with phenobarbital
Coadministration with phenytoin
Coadministration with rifampin
Coadministration with rifapentine
Coadministration with dexamethasone (more than a single dose)
Coadministration with St. John's wort
Coadministration with proton pump inhibitors

Drug Interactions

579View drug interactions

2898View drug interactions

Adverse Reactions

Most common (>=1%) Injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back pain, upper respiratory tract infection

Serious Hypersensitivity reactions, hepatotoxicity, depressive disorders including depression, suicidal ideation, and suicide attempt

Postmarketing Hypersensitivity reactions (angioedema, urticaria), Stevens-Johnson syndrome/toxic epidermal necrolysis

Most common (>=2%) Headache, sleep disturbances

Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome

Postmarketing Weight increased, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome

Pharmacology

Cabotegravir is an HIV integrase strand transfer inhibitor (INSTI) that inhibits HIV replication by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for the HIV replication cycle.

Odefsey is a fixed-dose combination of emtricitabine (an NRTI that inhibits HIV-1 reverse transcriptase by chain termination), rilpivirine (an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase), and tenofovir alafenamide (a prodrug that is converted to tenofovir, an NRTI inhibiting HIV-1 reverse transcriptase by chain termination).

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Apretude